Aloxistatin
Cat.No:IA3190 Solarbio
CAS:88321-09-9
Molecular Formula:C17H30N2O5
Molecular Weight:342.43
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Metabolic Enzyme & Protease >
AloxistatinCAS:88321-09-9
Molecular Formula:C17H30N2O5
Molecular Weight:342.43
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 88321-09-9 |
Name | Aloxistatin |
Molecular Formula | C17H30N2O5 |
Molecular Weight | 342.43 |
Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD00132883 |
SMILES | O=C([C@H]1O[C@@H]1C(N[C@H](C(NCCC(C)C)=O)CC(C)C)=O)OCC |
Target Point | Cysteine protease |
Passage | Metabolic Enzyme&Protease |
Background | It is an irreversible membrane permeable cysteine protease inhibitor with the activity of inhibiting platelet aggregation. |
Biological Activity | Aloxistatin (E64d) 是可渗透细胞,不可逆的广谱半胱氨酸蛋白酶 (cysteine protease) 抑制剂。[1-5] |
Data Literature Source | [1]. Doh-Ura K,et al. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74(10):4894-7. [2]. Konjar S,et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131(2):257-67. [3]. Mullins SR,et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393(12):1405-16. [4]. Hook G,et al. The cysteine protease inhibitor,E64d,reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B,but not BACE1,β-secretase activity. J Alzheimers Dis. 2011;26(2):387-408. [5]. Cheng XW,et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173(2):358-69. |
Unit | Bottle |
Specification | 1mg 2mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.